Study notes drug resistance to telaprevir in hepatitis C patients

05/6/2010 | Bloomberg

Some hepatitis C patients developed resistance to Vertex Pharmaceuticals' telaprevir after two days of treatment and had to take multidrug cocktails to sustain the medicine's effectiveness, a study showed. Researchers found that telaprevir kills off normal viral particles along with rapidly mutating ones, but resistant mutants are left to multiply.

View Full Article in:

Bloomberg

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Executive Officer
CarePoint Health Plan
Jersey City, NJ
Regional Director, Southeastern Region - State Affairs
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Director, Compliance - Health Plan Privacy & Security
Kaiser Permanente
Oakland, CA